Proteins and Peptides

23 June 2020

Neoleukin Therapeutics Presents Preclinical Data for NL-201 and De Novo Protein Design Technology at American Association for Cancer Research (AACR) Virtual Annual Meeting II

23 June 2020

Bicycle Therapeutics Presents New Translational Data for BT5528 and Preclinical Data for Tumor-targeted Immune Cell Agonists at AACR Virtual Annual Meeting II

23 June 2020

FDA Accepts Supplemental Biologics License Application (sBLA) for BOTOX® (onabotulinumtoxinA) for the Treatment of Pediatric Patients with Neurogenic Detrusor Overactivity

22 June 2020

SOTIO Presents New Data Showing Strong Anti-tumor Effect of IL-15 Superagonist SO-C101 in Mice at 2020 AACR Virtual Annual Meeting II

18 June 2020

Novo Nordisk successfully completes AM833 phase 2 trial and phase 1 combination trial with AM833 and semaglutide in obesity

18 June 2020

Xeris Pharmaceuticals Announces Positive Topline Results from the Phase 2 Comparative Study of a Novel Pramlintide-insulin Co-formulation (XP-3924) in Adults with Type 1 Diabetes Mellitus

18 June 2020

Innovent Announces First Patient Dosed in A Phase 1b/2 Clinical Trial of IBI362, a Dual GLP-1 and Glucagon Receptor Agonist, in China

18 June 2020

Agalsidase Beta BS I.V. Infusion [JCR] (JR-051) for Fabry Disease: Notice on the Publication of the Results of the Phase 1 and 2/3 Clinical Trials in Molecular Genetics and Metabolism

16 June 2020

FDA approves Lyumjev™ (insulin lispro-aabc injection), Lilly’s new rapid-acting insulin

15 June 2020

Xeris Pharmaceuticals Announces Positive Results From the Outpatient Stage of a Phase 2 Study of Its Developmental Gvoke Ready-to-Use (RTU) Micro™ Glucagon in Adults at Risk of Hypoglycemia During and After Aerobic Exercise

15 June 2020

Arecor presents positive results for the first phase I clinical trial of AT247, a novel ultra-rapid acting insulin

15 June 2020

Investigational, once-weekly insulin icodec showed comparable efficacy and safety to once-daily insulin glargine U100 in phase 2 trial

13 June 2020

New Pivotal Data Demonstrate Superiority of Apellis’ Pegcetacoplan to Eculizumab in Improving Hemoglobin Levels, Independent of Prior Transfusions, in PNH

13 June 2020

Semaglutide 2.4 mg shows superior weight loss versus placebo in the phase 3 trials STEP 2 and STEP 3, thereby successfully completing the programme

13 June 2020

Noveome Biotherapeutics Announces Positive Data for Phase 2 Clinical Trial of ST266 in Patients with Persistent Corneal Epithelial Defects

12 June 2020

Sobi and Selecta announce strategic licensing agreement for SEL-212, a phase 3-ready novel treatment for Chronic Refractory Gout

12 June 2020

Mylan and Biocon Announce U.S. FDA Approval of Semglee™ (insulin glargine injection)

11 June 2020

Lannett Provides Update On Clinical Advancement Of Biosimilar Insulin Glargine, Following FDA Meeting

11 June 2020

FDA Approves Pfizer’s Oncology Supportive Care Biosimilar, NYVEPRIA™ (pegfilgrastim-apgf)

9 June 2020

First patient dose delivered for Lilly’s tirzepatide cardiovascular outcomes trial

5 June 2020

Data Presented from Phase 1b Study of NKTR-358, a Novel T Regulatory Cell Stimulator, at Annual European Congress of Rheumatology (EULAR 2020)

5 June 2020

Novo Nordisk reports weight loss of 14.9% (16.9% if taken as intended) in STEP 1 trial

2 June 2020

Relief Therapeutics and NeuroRx Announce Enrollment of First Patients with RLF- 100 in Phase 2b/3 Clinical Trial in Patients with COVID-19 Associated Acute Respiratory Distress

1 June 2020

Histogen Announces First Patient Dosed in Phase 1b/2a Trial of HST 001 for Androgenic Alopecia

1 June 2020

Study Demonstrating Role of IdeS in Enabling of Gene Therapy in the Presence of Neutralizing Anti-AAV Antibodies Published in Nature Medicine

1 June 2020

Revance and Mylan to Advance Development Program for Biosimilar to BOTOX®

30 May 2020

Medicenna Presents Data on MDNA11, an IL-2 Superkine at ASCO 2020

28 May 2020

Pivotal Phase III trial of abaloparatide-SC in Japanese women and men with osteoporosis achieves primary endpoint

28 May 2020

FDA Accepts for Review Fresenius Kabi’s BLA Submission for Pegfilgrastim Biosimilar

28 May 2020

PhaseBio Launches Clinical Trial to Evaluate PB1046 as a Treatment for Hospitalized COVID-19 Patients

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

Pembrolizumab (Keytruda) Biosimilar Antibody Pipeline Review

Masked Antibodies & Cytokines As Prodrugs: a landscape analysis of stakeholders, technologies, pipelines, business and financing from an industry perspective

PSMA-Targeted Therapy Pipeline Review

Adalimumab (Humira) Biosimilars Pipeline Review

Targeted Protein Degradation by Proteasomal, Lysosomal & Autophagy Pathways 2022: an industry landscape analysis of stakeholders, technologies, pipeline, partnering and financing

2023 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

CD73 Inhibitor Pipeline Review

Folate Receptor alpha (FRα) Targeted Therapy Pipeline Review

Antibody Target, Technology & Pipeline Database: 1-Year Subscription

Claudin 18.2-Targeted Immunotherapy: a landscape analysis of stakeholders, drug modalities, pipeline and business opportunities from an industry perspective